ZIAC SIDE EFFECTS
- Generic Name: bisoprolol and hydrochlorothiazide
- Brand Name: Ziac
- Drug Class: Thiazide Combos
SIDE EFFECTS
ZIAC
Bisoprolol fumarate/HCTZ 6.25 mg is well tolerated in most patients. Most adverse effects (AEs) have been mild and transient. In more than 65,000 patients treated worldwide with bisoprolol fumarate, occurrences of bronchospasm have been rare. Discontinuation rates for AEs were similar for bisoprolol fumarate/HCTZ 6.25 mg and placebo-treated patients.
In the United States, 252 patients received bisoprolol fumarate (2.5, 5, 10, or 40 mg)/HCTZ 6.25 mg and 144 patients received placebo in two controlled trials. In Study 1, bisoprolol fumarate 5/HCTZ 6.25 mg was administered for 4 weeks. In Study 2, bisoprolol fumarate 2.5, 10, or 40/HCTZ 6.25 mg was administered for 12 weeks. All adverse experiences, whether drug related or not, and drug related adverse experiences in patients treated with bisoprolol fumarate 2.510/HCTZ 6.25 mg, reported during comparable, 4 week treatment periods by at least 2% of bisoprolol fumarate/HCTZ 6.25 mg-treated patients (plus additional selected adverse experiences) are presented in the following table:
Body System/ Adverse Experience | % of Patients with Adverse Experiencesa | |||
All Adverse Experiences | Drug Related Adverse Experiences | |||
Placebob | B2.5-40/H6.25b | Placebob | B2.5-10/H6.25b | |
(n=144) | (n=252) | (n=144) | (n=221) | |
% | % | % | % | |
Cardiovascular | ||||
bradycardia | 0.7 | 1.1 | 0.7 | 0.9 |
arrhythmia | 1.4 | 0.4 | 0.0 | 0.0 |
peripheral ischemia | 0.9 | 0.7 | 0.9 | 0.4 |
chest pain | 0.7 | 1.8 | 0.7 | 0.9 |
Respiratory | ||||
bronchospasm | 0.0 | 0.0 | 0.0 | 0.0 |
cough | 1.0 | 2.2 | 0.7 | 1.5 |
rhinitis | 2.0 | 0.7 | 0.7 | 0.9 |
URI | 2.3 | 2.1 | 0.0 | 0.0 |
Body as a Whole | ||||
asthenia | 0.0 | 0.0 | 0.0 | 0.0 |
fatigue | 2.7 | 4.6 | 1.7 | 3.0 |
peripheral edema | 0.7 | 1.1 | 0.7 | 0.9 |
Central Nervous System | ||||
dizziness | 1.8 | 5.1 | 1.8 | 3.2 |
headache | 4.7 | 4.5 | 2.7 | 0.4 |
Musculoskeletal | ||||
muscle cramps | 0.7 | 1.2 | 0.7 | 1.1 |
myalgia | 1.4 | 2.4 | 0.0 | 0.0 |
Psychiatric | ||||
insomnia | 2.4 | 1.1 | 2.0 | 1.2 |
somnolence | 0.7 | 1.1 | 0.7 | 0.9 |
loss of libido | 1.2 | 0.4 | 1.2 | 0.4 |
impotence | 0.7 | 1.1 | 0.7 | 1.1 |
Gastrointestinal | ||||
diarrhea | 1.4 | 4.3 | 1.2 | 1.1 |
nausea | 0.9 | 1.1 | 0.9 | 0.9 |
dyspepsia | 0.7 | 1.2 | 0.7 | 0.9 |
a Averages adjusted to combine across studies. b Combined across studies. |
Other adverse experiences that have been reported with the individual components are listed below.
Bisoprolol Fumarate
In clinical trials worldwide, or in postmarketing experience, a variety of other AEs, in addition to those listed above, have been reported. While in many cases it is not known whether a causal relationship exists between bisoprolol and these AEs, they are listed to alert the physician to a possible relationship.
Central Nervous System
Unsteadiness, dizziness, vertigo, headache, syncope, paresthesia, hypoesthesia, hyperesthesia, sleep disturbance/vivid dreams, insomnia, somnolence, depression, anxiety/restlessness, decreased concentration/memory.
Cardiovascular
Bradycardia, palpitations and other rhythm disturbances, cold extremities, claudication, hypotension, orthostatic hypotension, chest pain, congestive heart failure, dyspnea on exertion.
Gastrointestinal
Gastric/epigastric/abdominal pain, peptic ulcer, gastritis, dyspepsia, nausea, vomiting, diarrhea, constipation, dry mouth.
Musculoskeletal
Arthralgia, muscle/joint pain, back/neck pain, muscle cramps, twitching/tremor.
Skin
Rash, acne, eczema, psoriasis, skin irritation, pruritus, purpura, flushing, sweating, alopecia, dermatitis, exfoliative dermatitis (very rarely), cutaneous vasculitis.
Special Senses
Visual disturbances, ocular pain/pressure, abnormal lacrimation, tinnitus, decreased hearing, earache, taste abnormalities.
Metabolic
Gout.
Respiratory
Asthma, bronchospasm, bronchitis, dyspnea, pharyngitis, rhinitis, sinusitis, URI (upper respiratory infection).
Genitourinary
Decreased libido/impotence, Peyronie’s disease (very rarely), cystitis, renal colic, polyuria.
General
Fatigue, asthenia, chest pain, malaise, edema, weight gain, angioedema.
In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents and should be considered potential adverse effects:
Central Nervous System
Reversible mental depression progressing to catatonia, hallucinations, an acute reversible syndrome characterized by disorientation to time and place, emotional lability, slightly clouded sensorium.
Allergic
Fever, combined with aching and sore throat, laryngospasm, and respiratory distress.
Hematologic
Agranulocytosis, thrombocytopenia.
Gastrointestinal
Mesenteric arterial thrombosis and ischemic colitis.
Miscellaneous
The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with bisoprolol fumarate during investigational use or extensive foreign marketing experience.
Hydrochlorothiazide
The following adverse experiences, in addition to those listed in the above table, have been reported with hydrochlorothiazide (generally with doses of 25 mg or greater).
General
Weakness.
Central Nervous System
Vertigo, paresthesia, restlessness.
Cardiovascular
Orthostatic hypotension (may be potentiated by alcohol, barbiturates, or narcotics).
Gastrointestinal
Anorexia, gastric irritation, cramping, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis, cholecystitis, sialadenitis, dry mouth.
Musculoskeletal
Muscle spasm.
Hypersensitive Reactions
Purpura, photosensitivity, rash, urticaria, necrotizing angiitis (vasculitis and cutaneous vasculitis), fever, respiratory distress including pneumonitis and pulmonary edema, anaphylactic reactions.
Special Senses
Transient blurred vision, xanthopsia.
Metabolic
Gout.
Genitourinary
Sexual dysfunction, renal failure, renal dysfunction, interstitial nephritis.
Skin
Erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis.
Postmarketing Experience
Non-Melanoma Skin Cancer
Hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for squamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk for SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and for white patients taking a cumulative dose of ≥50,000 mg the risk increase was approximately 1 additional SCC case for every 6,700 patients per year.
Laboratory Abnormalities
ZIAC
Because of the low dose of hydrochlorothiazide in ZIAC (bisoprolol fumarate and hydrochlorothiazide), adverse metabolic effects with bisoprolol fumarate/HCTZ 6.25 mg are less frequent and of smaller magnitude than with HCTZ 25 mg. Laboratory data on serum potassium from the U.S. placebo-controlled trials are shown in the following table:
Serum Potassium Data from U.S. Placebo Controlled Studies | |||||
Placeboa | B2.5/ H6.25 mg | B5/ H6.25 mg | B10/ H6.25 mg | HCTZ 25 mga | |
(N=130b) | (N=28b) | (N=149b) | (N=28b) | (N=142b) | |
Potassium | |||||
Mean Changec (mEq/L) | +0.04 | +0.11 | -0.08 | 0.00 | -0.30% |
Hypokalemiad | 0.0% | 0.0% | 0.7% | 0.0% | 5.5% |
a Combined across studies. b Patients with normal serum potassium at baseline. c Mean change from baseline at Week 4. d Percentage of patients with abnormality at Week 4. |
Treatment with both beta blockers and thiazide diuretics is associated with increases in uric acid. However, the magnitude of the change in patients treated with B/H 6.25 mg was smaller than in patients treated with HCTZ 25 mg. Mean increases in serum triglycerides were observed in patients treated with bisoprolol fumarate and hydrochlorothiazide 6.25 mg. Total cholesterol was generally unaffected, but small decreases in HDL cholesterol were noted.
Other laboratory abnormalities that have been reported with the individual components are listed below.
Bisoprolol Fumarate
In clinical trials, the most frequently reported laboratory change was an increase in serum triglycerides, but this was not a consistent finding.
Sporadic liver test abnormalities have been reported. In the U.S. controlled trials experience with bisoprolol fumarate treatment for 4-12 weeks, the incidence of concomitant elevations in SGOT and SGPT from 1 to 2 times normal was 3.9%, compared to 2.5% for placebo. No patient had concomitant elevations greater than twice normal.
In the long-term, uncontrolled experience with bisoprolol fumarate treatment for 6-18 months, the incidence of one or more concomitant elevations in SGOT and SGPT from 1 to 2 times normal was 6.2%. The incidence of multiple occurrences was 1.9%. For concomitant elevations in SGOT and SGPT of greater than twice normal, the incidence was 1.5%. The incidence of multiple occurrences was 0.3%. In many cases these elevations were attributed to underlying disorders, or resolved during continued treatment with bisoprolol fumarate.
Other laboratory changes included small increases in uric acid, creatinine, BUN, serum potassium, glucose, and phosphorus and decreases in WBC and platelets. There have been occasional reports of eosinophilia. These were generally not of clinical importance and rarely resulted in discontinuation of bisoprolol fumarate.
As with other beta-blockers, ANA conversions have also been reported on bisoprolol fumarate. About 15% of patients in long-term studies converted to a positive titer, although about one-third of these patients subsequently reconverted to a negative titer while on continued therapy.
Hydrochlorothiazide
Hyperglycemia, glycosuria, hyperuricemia, hypokalemia and other electrolyte imbalance, hyperlipidemia, hypercalcemia, leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia, and hemolytic anemia have been associated with HCTZ therapy.
SRC: NLM .